MOSCOW, Jan. 28, 2014 /PRNewswire/ -- Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.
At meetings initiated by Governor Oleg Korolev of Lipetsk, Management from Rafarma and Pharmsynthez have agreed in principal to commence a 'joint venture production plan', with the potential to substantially increase revenues for both companies. The agreement is contingent upon a satisfactory technical audit of Rafarma's facilities by Pharmsynthez to be conducted next month.
The joint venture production plan calls for various Pharmsynthez pharmaceutical products to be manufactured in Rafarma's facilities, almost doubling capacity and expanding market share accordingly. The Ontological and Antibiotic products to be produced currently have domestic revenues of approximately $250,000,000. While Pharmsynthez has an existing market share of approximately 20%, the joint venture production plan with Rafarma anticipates increasing market share to 35% or more.
"Rafarma's state-of-the-art facility is a sought-after partner in the rapidly-growing Russian pharmaceutical industry and our expanding portfolio of products continues to draw attention from industry participants and investors alike," stated Rafarma CEO Dave Anderson.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation's domestic pharmaceutical industry. Rafarma's mission is to work under the auspices of these aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://rafarma.com
Founded in 1996, Pharmsynthez became a fully operational research and production facility in 2001 and is currently conforming to GMP and GOST R 52249-2004 standards of pharmaceutical manufacture and quality control. Pharmsynthez currently produces Neovir®, Segidrin®, Fenasid® and Penkrofton® used in oncology, gynecology, treatment of immunodeficiencies and tuberculosis.
For more information on Pharmsynthez, visit: http://en.pharmsynthez.com/Pharmsynthez.3.html
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
SOURCE Rafarma Pharmaceuticals, Inc.